ABSTRACT
Plant-mediated green synthesis is a cost-effective and eco-friendly process used to synthesize metallic nanoparticles. Experimental pH is of interest due to its ability to influence nanoparticle size and shape; however, little has been explored in comparison to the influence of this parameter on the therapeutic potential of resultant metallic nanoparticles. Our work investigated the influence of pH alternation on antimicrobial properties of plant-mediated green synthesized (using Spinacia oleracea leaf extract) silver nanoparticles. We further investigated if the antimicrobial activity was sustained at 8 weeks (after initial green synthesis). Antimicrobial properties were evaluated against Escherichia coli, Staphylococcus aureus, and Candida albicans. Our work confirmed that experimental pH in plant-mediated green synthesis of silver nanoparticles influenced their resultant antimicrobial properties. Silver nanoparticles generated at experimental pH 4,5, and nine showed activity against E. coli which was sustained at various levels over 8 weeks. No antimicrobial activity was observed against S. aureus, and weak antimicrobial activity against C. albicans. These interesting findings highlight the importance of experimental pH. Further understanding of the role experimental pH plays on resultant metallic nanoparticle properties as it relates to biological and therapeutic impact is required, which will have an impact on wider applications beyond antimicrobial activity.
ABSTRACT
Substandard and falsified (SF) medicines are a global health challenge with the World Health Organization (WHO) estimating that 1 in 10 of medicines in low- and middle-income countries (LMICs) are SF. Antimicrobials (i.e. antimalarials, antibiotics) are the most commonly reported SF medicines. SF medicines contribute significantly to the global burden of infectious diseases and antimicrobial resistance (AMR). This article discusses the challenges associated with the global impact of SF and unregistered/unlicensed antimicrobials with a focus on anti-TB medicines. Tuberculosis (TB) is the 13th leading cause of death worldwide, and is currently the second leading cause of death from a single infectious agent, ranking after COVID-19 and above HIV/AIDS. Specifically in the case of TB, poor quality of anti-TB medicines is among the drivers of the emergence of drug-resistant TB pathogens. In this article, we highlight and discuss challenges including the emergence of SF associated AMR, patient mistrust and lack of relevant data. We also present study reports to inform meaningful change. Recommended solutions involve the adaptation of interventions from high-income countries (HICs) to LMICS, the need for improvement in the uptake of medication authentication tools in LMICs, increased stewardship, and the need for global and regional multidisciplinary legal and policy cooperation, resulting in improved legal sanctions.
